Xvivo Perfusion AB (publ)
XVIPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -4.61 | -12.60 | 1.43 | -1.72 |
| FCF Yield | 0.00% | 0.10% | -0.16% | 0.43% |
| EV / EBITDA | 153.47 | 1,219.08 | 345.07 | 901.60 |
| Quality | ||||
| ROIC | 0.24% | -0.15% | 1.08% | 0.51% |
| Gross Margin | 66.57% | 74.40% | 73.37% | 76.96% |
| Cash Conversion Ratio | 4.74 | -2.63 | 1.09 | 1.25 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.98% | 16.27% | 22.66% | 25.58% |
| Free Cash Flow Growth | -100.00% | 157.69% | -124.57% | 171.39% |
| Safety | ||||
| Net Debt / EBITDA | -4.33 | -43.96 | -11.89 | -24.67 |
| Interest Coverage | 5.83 | 0.68 | 0.65 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.22 | 0.17 | 0.26 | 0.23 |
| Cash Conversion Cycle | 303.44 | 590.79 | 425.24 | 374.89 |